Cargando…
PD-L1-Positive High-Grade Triple-Negative Breast Cancer Patients Respond Better to Standard Neoadjuvant Treatment—A Retrospective Study of PD-L1 Expression in Relation to Different Clinicopathological Parameters
Triple negative breast cancer (TNBC) is typically a high-grade breast cancer with poorest clinical outcome despite available treatment modalities with chemo-, immuno- and radiotherapy. The status of tumor-infiltrating lymphocytes (TILs) is a prognostic factor closely related to programmed death liga...
Autores principales: | Stanowska, Olga, Kuczkiewicz-Siemion, Olga, Dębowska, Małgorzata, Olszewski, Wojciech P., Jagiełło-Gruszfeld, Agnieszka, Tysarowski, Andrzej, Prochorec-Sobieszek, Monika |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9573147/ https://www.ncbi.nlm.nih.gov/pubmed/36233396 http://dx.doi.org/10.3390/jcm11195524 |
Ejemplares similares
-
Small Biopsy Samples: Are They Representative for Biphenotypic Sinonasal Sarcoma?
por: Kuczkiewicz-Siemion, Olga, et al.
Publicado: (2022) -
Immunoexpression of PD-L1 and PD-1 and Its Clinicopathological Correlation in Urothelial Carcinomas
por: Kumar, Utpal, et al.
Publicado: (2021) -
Integrative assessment of clinicopathological parameters and the expression of PD-L1, PD-L2 and PD-1 in tumor cells of retroperitoneal sarcoma
por: Miyake, Makito, et al.
Publicado: (2020) -
Clinicopathological assessment of PD-1/PD-L1 immune checkpoint expression in desmoid tumors
por: Hashimoto, Kazuhiko, et al.
Publicado: (2023) -
The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials
por: Wu, Dawei, et al.
Publicado: (2022)